Several clinical trials are ongoing evaluating the effectiveness of Bcl-2 inhibition in combination with conventional chemotherapy agents in T-ALL (NCT00501826 [119]; NCT03808610, NCT03504644 [122]). The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.